Extended adjuvant endocrine therapy in hormone dependent breast cancer: The paradigm of the NCIC-CTG MA.17/BIG 1-97 trial

Critical Reviews in Oncology/Hematology

Volumn 86, Issue 1, 2013, Pages 23-32

  Higgins, Michaela J ^a   Liedke, Pedro E R ^a,b   Goss, Paul E ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Extended adjuvant endocrine therapy; MA.17

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM; ESTROGEN RECEPTOR; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TRIACYLGLYCEROL; VITAMIN D;

ADJUVANT THERAPY; ALOPECIA; ANOREXIA; ARTHRALGIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LYMPH NODE METASTASIS; MYALGIA; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN; TRIAZOLES;

EID: 84875053024     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.09.013     Document Type: Review

References (61)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
3. Kennecke H., Yerushalmi R., Woods R., et al. Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology 2010, 28:3271-3277.
4. Kennecke H.F., Olivotto I.A., Speers C., et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Annals of Oncology 2007, 18:45-51.
5. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. Journal of the National Cancer Institute 2001, 93:684-690.
6. Tormey D.C., Gray R., Falkson H.C. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group. Journal of the National Cancer Institute 1996, 88:1828-1833. [see comments].
7. Peto RD, on behalf of the ATLAS Collaboration: ATLAS (Adjuvant Tamoxifen, Longer Against Shorter). International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women preliminary results. Breast Cancer Res Treat 2007;106.
8. Dowsett M., Cuzick J., Ingle J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology 2009, 28:509-518.
9. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
10. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 2005, 353:2747-2757.
11. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
12. Amir E., Seruga B., Niraula S., et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Journal of the National Cancer Institute 2011, 103:1299-1309.
13. Regan M.M., Neven P., Giobbie-Hurder A., et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncology 2011, 12:1101-1108.
14. Anderson B.O., Cazap E. Breast health global initiative (BHGI) outline for program development in Latin America. Salud Publica de Mexico 2009, 51(Suppl 2):s309-s315.
15. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 2003, 349:1793-1802.
16. Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. Journal of Clinical Oncology 2008, 26:1965-1971.
17. Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. Journal of the National Cancer Institute 2007, 99:1845-1853.
18. Goss P.E., Muss H.B., Ingle J.N., et al. Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clinical Breast Cancer 2008, 8(5):411-417.
19. Chia S.K., Speers C.H., Bryce C.J., et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. Journal of Clinical Oncology 2004, 22:1630-1637.
20. Brewster A.M., Hortobagyi G.N., Broglio K.R., et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. Journal of the National Cancer Institute 2008, 100:1179-1183.
21. Davies C., Godwin J., Gray R., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
22. Hortabagyi G., Kau S.W., Buzdar A.U., Theriault R.L., Booser D.J., Gwyn K., Valero V. What is the prognosis of patients with operable breast cancer five years after diagnosis?. Journal of Clinical Oncology 2004, 22. [Abst. 585].
23. Freedman G.M., Anderson P., Li T., et al. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen. Cancer 2006, 107:2552-2558.
24. Lamerato L., Havstad S., Gandhi S., et al. Breast cancer recurrence and related mortality in US patients with early breast cancer. Journal of Clinical Oncology 2005, 23. [Abst. 738].
25. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute 2005, 97:1262-1271.
26. Wasan K.M., Goss P.E., Pritchard P.H., et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Annals of Oncology 2005, 16:707-715.
27. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. Journal of Clinical Oncology 2006, 24:3629-3635.
28. Pater J., Tu D., Shepherd L., et al. Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Research and Treatment 2008, 108:265-269.
29. Ingle J.N., Tu D., Pater J.L., et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of Oncology 2008, 19:877-882.
30. Jin H., Tu D., Zhao N., et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. Journal of Clinical Oncology 2011.
31. Colleoni M., Giobbie-Hurder A., Regan M.M., et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. Journal of Clinical Oncology 2011, 29:1117-1124.
32. Muss H.B., Tu D., Ingle J.N., et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. Journal of Clinical Oncology 2008, 26:1956-1964.
33. Smith I.E., Dowsett M., Yap Y.-S., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. Journal of Clinical Oncology 2006, 24:2444-2447.
34. Goss P.E., Ingle J.N., Martino S., Robert N., Muss H., Shepherd L., Pritchard K.I., Livingston R.B., Davidson N., Perez E.A., Cameron D., Whelan T., Palmer M., Tu D. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 trial. San Antonio Breast Cancer Symposium 2009.
35. Goss P.E., Ingle J.N., Martino S., et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. Journal of Clinical Oncology 2007, 25:2006-2011.
36. Dowsett M., Cuzick J., Wale C., et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. Journal of Clinical Oncology 2005, 23:7512-7517.
37. Viale G., Regan M., Dell'Orto P., et al. Central review of ER, PgR, and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Research and Treatment 2005, 94(Suppl 1).
38. Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616.
39. Ma X.J., Hilsenbeck S.G., Wang W., et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. Journal of Clinical Oncology 2006, 24:4611-4619.
40. Goetz M.P., Suman V.J., Ingle J.N., et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clinical Cancer Research 2006, 12:2080-2087.
41. Ma X.J., Salunga R., Dahiya S., et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clinical Cancer Research 2008, 14:2601-2608.
42. Jerevall P.L., Ma X.J., Li H., et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. British Journal of Cancer 2011, 104:1762-1769.
43. Sgroi D., Carney E., Richardson E., et al. Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort. Journal of Clinical Oncology 2011, 29. [abstr 2].
44. Ingle J.N., Tu D., Pater J.L., et al. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Research and Treatment 2006, 99:295-300.
45. Goss P.E., Ingle J.N., Pater J.L., et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. Journal of Clinical Oncology 2008, 26:1948-1955.
46. Wardley A.M. Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17. Clinical Breast Cancer 2006, 6(Suppl 2):S45-S50.
47. Chapman J.A., Meng D., Shepherd L., et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. Journal of the National Cancer Institute 2008, 100:252-260.
48. Amir E., Seruga B., Niraula S., Carlsson L., Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Journal of the National Cancer Institute 2011, 103:1299-1309.
49. Love R.R., Wiebe D.A., Newcomb P.A., et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Annals of Internal Medicine 1991, 115:860-864.
50. Grey A.B., Stapleton J.P., Evan M.C., Reid I.R. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1995, 80:3191-3195.
51. Goss P.E., Ingle J.N., Ales-Martinez J.E., et al. Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine 2011, 364:2381-2391.
52. Goss P.E., Powles T.J., Dowsett M., et al. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report. Cancer Research 1986, 46:4823-4826.
53. Whelan T.J., Goss P.E., Ingle J.N., et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. Journal of Clinical Oncology 2005, 23:6931-6940.
54. Kung H.C., Hoyert D.L., Xu J.Q., Murphy S.L. Deaths: final data for 2005. National vital statistics reports 2008, National Center for Health Statistics, Hyattsville, MD.
55. Kannel W.B. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. American Heart Journal 1987, 114:413-419.
56. Levi F., Randimbison L., Te V.C., et al. Long-term mortality of women with a diagnosis of breast cancer. Oncology 2002, 63:266-269.
57. Delea T.E., Karnon J., Smith R.E., et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. American Journal of Managed Care 2006, 12:374-386.
58. Karnon J., Delea T., Johnston S.R., et al. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 2006, 24:237-250.
59. El Ouagari K., Karnon J., Delea T., et al. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Research and Treatment 2007, 101:37-49.
60. Markopoulos C., Dafni U., Misitzis J., et al. Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy. Breast Cancer Research 2009, 11:R35.
61. Goss P., Mamounas E., Jakesz R., Markopoulos C., Dowsett M., Peto R., Godwin J., Davies C. Aromatase Inhibitors (AIs) versus not (placebo/observation) as late extended adjuvant therapy for postmenopausal women with early stage breast cancer (BC): overviews of randomized trials of AIs after ∼5 years of tamoxifen. San Antonio Breast Cancer Symposium 2009.